Engineering cardiac regeneration using stem cells: Cellular sources, differentiation signatures, targeted delivery, and functional recovery
Gupta S., Faiyazuddin M., Gupta V., Tanwar R., Rani P., Almagharbeh WT.
Narrative Review on Cardiovascular Disease, Immune Modulation, published in Regen Ther (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Regen Ther (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42125407
- PMCID
- PMC13158422
- DOI
- 10.1016/j.reth.2026.101120
Abstract (original English)
Cardiovascular diseases remain the leading cause of mortality worldwide, and the limited regenerative capacity of the adult heart continues to delay functional recovery, resulting in myocardial injury. Stem cell-based therapies offer a promising avenue for cardiac repair through mechanisms that include cardiomyogenic differentiation, paracrine signaling, angiogenic stimulation, and immunomodulation. Although pluripotent stem cells, mesenchymal stem cells, and cardiac progenitor cells have demonstrated significant benefits in preclinical models, clinical translation has yielded modest functional improvements, mainly due to poor cell retention, electrical and structural immaturity of transplanted cells, immune-mediated clearance, and concerns regarding tumorigenicity and arrhythmogenicity. Therapeutic efficacy largely derives from extracellular vesicles, secreted microRNAs, pro-survival cytokines, and other bioactive substances released by cells. Direct replacement of cardiomyocytes is challenging because the host tissue environment limits the acceptance and stable integration of exogenous cells. Novel engineered cardiac patches, biomaterial-assisted cell delivery, gene-edited progenitor transplantation, exosome therapeutics, and cell-free therapy are improving safety, the plausibility of cell transplantation, and the precision of tissue targeting. Despite those biotech improveme
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level AMeta-analysisEurope PMC
Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Orally derived mesenchymal stem cells in the treatment of vascular diseases: a systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Sci Rep (2026) — summary generated from the PubMed abstract.
- 2026
Sci Rep - Level ASystematic ReviewEurope PMC
From Preservation to Repair: A Systematic Review of Therapeutic Organ Rehabilitation During Normothermic Ex Vivo Machine Perfusion
Systematic Review with a reported sample of 12 on Cardiovascular Disease, Immune Modulation, published in Transplant Direct (2026) — summary generated from the PubMed abstract.
- 2026
- n = 12
Transplant Direct - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev